Dr. Adnan Mjalli
Founder and CEO, Mjalli Investment Group USA
Dr. Mjalli is an internationally recognized entrepreneur in the business of drug discovery & development of new medicines in the pharmaceutical & biotechnology industry. He is the founder of TransTech Pharma, LLC, High Point Pharmaceuticals (both are drug discovery, development & commercialization companies now under vTv Therapeutics), High Point Clinical Trials Center (a clinical trials research & development center that conducts human clinical trials) and PharmaCore (a drug manufacturing company). He currently severs as CEO of High Point Clinical Trials Center and Chairman of PharmaCore. He obtained his PhD in Medicinal Chemistry in 1989 from the University of Exeter, UK. His postdoctoral work was carried out at the University of Rochester. Dr. Mjalli has held various positions of increasing responsibility in research & senior management at several pharmaceutical & biotechnology companies including Merck & Co. & Ontogen Corporation. He is the author of more than 40 scientific papers, four book chapters & an inventor of more than 700 patents & applications. Currently, Dr. Mjalli serves on the High Point University board, The Foundation Board of GTCC, High Point Chamber of Commerce, the Arab American University, the American Task Force on Palestine, the America-Mideast Educational & Training Service, a member of the American Chemical Society, an honorary fellow of the Islamic World Academy of Sciences & the Palestine Academy of Science & Technology.